Compare American International Group Inc (AIG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American International Group Inc vs Merck & Co., Inc. — how do they compare? American International Group Inc trades at $80.5 (market cap $42.98B), while Merck & Co., Inc. trades at $125.66 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 7.4× American International Group Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| AIG | MRK | |
|---|---|---|
Market Cap | $42.98B | $318.26B |
Sector | Financials | Health |
52-Week High | $86.59 | $129.52 |
52-Week Low | $71.89 | $77.60 |
Enterprise Value | $50.68B | $361.68B |
Dividend Yield | 2.47% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
Merck (MRK) trades at $126.78, showing stable recent performance with strong institutional interest. The company demonstrates solid fundamentals with 2025 revenue of $65.01B and net income of $18.25B, representing a 28.07% profit margin. Recent earnings have consistently beaten expectations, and the company is actively expanding through strategic acquisitions like Terns Pharmaceuticals. Technical indicators show a bullish trend with moving averages supporting upward momentum, though oscillators suggest some consolidation may be needed.
Merck presents a compelling investment case with strong profitability, consistent earnings beats, and strategic pipeline expansion through M&A. The stock offers 9.9% upside to the consensus price target of $139.33, supported by 67.6% analyst buy ratings. Key risks include patent expirations, competitive pressures in oncology, and integration challenges from recent acquisitions. The company's robust cash flow generation supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
